Both proteases and kinases are considered druggable, signifying they are potential targets for developing medications that block their activity,’ says Lucas, associate professor of pathology at the U-M Medical College. MALT lymphomas that carry the API2-MALT1 fusion protein tend to be aggressive and more resistant to treatment. The effect is bigger tumors and increased spread through the entire body. The researchers discovered that once NIK turns into stable, it triggers a series of downstream reactions that produce cells more likely to metastasize and even more resistant to current treatments. These results were reversed when experts switched off NIK, suggesting that either blocking NIK or stopping NIK from becoming stable by blocking the proteins fusion, could halt the spread and development of MALT lymphoma tumors.Nagurney, M.D., M.P.H., J. Hector Pope, M.D., Thomas H. Hauser, M.D., M.P.H., Charles S. White, M.D., Scott G. Weiner, M.D., M.P.H., Shant Kalanjian, M.D., Michael E. Mullins, M.D., Issam Mikati, M.D., W. Frank Peacock, M.D., Pearl Zakroysky, B.A., Douglas Hayden, Ph.D., Alexander Goehler, M.D., Ph.D., Hang Lee, Ph.D., G. Scott Gazelle, M.D., M.P.H., Ph.D., Stephen D. Wiviott, M.D., Jerome L. Fleg, M.D., and James E. Udelson, M.D. For the ROMICAT-II Investigators: Coronary CT Angiography versus Regular Evaluation in Acute Chest Pain Treatment of patients with acute chest discomfort but an inconclusive initial evaluation with the use of biomarkers and electrocardiographic assessment is often diagnostically challenging and inefficient.